Published in Proc Natl Acad Sci U S A on October 10, 2012
Locus-specific epigenetic remodeling controls addiction- and depression-related behaviors. Nat Neurosci (2014) 1.30
Editing the epigenome: technologies for programmable transcription and epigenetic modulation. Nat Methods (2016) 1.24
Targets for future clinical trials in Huntington's disease: what's in the pipeline? Mov Disord (2014) 1.21
Applications of CRISPR-Cas systems in neuroscience. Nat Rev Neurosci (2015) 1.18
CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases. Mol Neurodegener (2015) 0.94
Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res (2014) 0.90
Enabling functional genomics with genome engineering. Genome Res (2015) 0.90
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases. Hum Gene Ther (2016) 0.84
Genome Engineering Using Adeno-associated Virus: Basic and Clinical Research Applications. Mol Ther (2015) 0.83
CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo. Mol Ther (2017) 0.80
Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity. Hum Mol Genet (2014) 0.80
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. Hum Mol Genet (2015) 0.80
Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol Neurodegener (2016) 0.79
Moving toward a gene therapy for Huntington's disease. Gene Ther (2015) 0.78
Engineered TAL Effector modulators for the large-scale gain-of-function screening. Nucleic Acids Res (2014) 0.76
Editing the Neuronal Genome: a CRISPR View of Chromatin Regulation in Neuronal Development, Function, and Plasticity. Yale J Biol Med (2016) 0.75
Concise review: carbon nanotechnology: perspectives in stem cell research. Stem Cells Transl Med (2013) 0.75
Huntington's disease: Molecular basis of pathology and status of current therapeutic approaches. Exp Ther Med (2016) 0.75
Translational synthetic biology. Syst Synth Biol (2015) 0.75
Directing an artificial zinc finger protein to new targets by fusion to a non-DNA-binding domain. Nucleic Acids Res (2015) 0.75
Genome Engineering with TALE and CRISPR Systems in Neuroscience. Front Genet (2016) 0.75
Modern Genome Editing Technologies in Huntington's Disease Research. J Huntingtons Dis (2017) 0.75
Transcriptional Signature of an Altered Purine Metabolism in the Skeletal Muscle of a Huntington's Disease Mouse Model. Front Physiol (2017) 0.75
Network analysis of human post-mortem microarrays reveals novel genes, microRNAs, and mechanistic scenarios of potential importance in fighting huntington's disease. Comput Struct Biotechnol J (2016) 0.75
Therapies targeting DNA and RNA in Huntington's disease. Lancet Neurol (2017) 0.75
Gene suppression approaches to neurodegeneration. Alzheimers Res Ther (2017) 0.75
Long-Term Assessment of AAV-Mediated Zinc Finger Nuclease Expression in the Mouse Brain. Front Mol Neurosci (2017) 0.75
Genome engineering: a new approach to gene therapy for neuromuscular disorders. Nat Rev Neurol (2017) 0.75
Repetitive zinc-binding domains in the protein transcription factor IIIA from Xenopus oocytes. EMBO J (1985) 20.39
Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell (2008) 11.24
Trinucleotide repeat disorders. Annu Rev Neurosci (2007) 9.45
Targeted genome editing in human cells with zinc finger nucleases constructed via modular assembly. Genome Res (2009) 8.69
Design and selection of novel Cys2His2 zinc finger proteins. Annu Rev Biochem (2001) 7.79
Krüppel-associated boxes are potent transcriptional repression domains. Proc Natl Acad Sci U S A (1994) 4.84
Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron (2012) 4.48
Standardized reagents and protocols for engineering zinc finger nucleases by modular assembly. Nat Protoc (2006) 4.16
Zinc Finger Tools: custom DNA-binding domains for transcription factors and nucleases. Nucleic Acids Res (2006) 3.95
Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet (2000) 3.87
Genome editing with modularly assembled zinc-finger nucleases. Nat Methods (2010) 3.79
The discovery of zinc fingers and their applications in gene regulation and genome manipulation. Annu Rev Biochem (2010) 3.75
In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature (1994) 3.31
Highly specific zinc finger proteins obtained by directed domain shuffling and cell-based selection. Proc Natl Acad Sci U S A (2003) 3.29
Inactivation of the mouse Huntington's disease gene homolog Hdh. Science (1995) 2.96
Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet (2000) 2.95
Getting a handhold on DNA: design of poly-zinc finger proteins with femtomolar dissociation constants. Proc Natl Acad Sci U S A (1998) 2.51
Comprehensive DNA recognition through concerted interactions from adjacent zinc fingers. Biochemistry (1998) 2.51
Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. Mol Ther (2009) 2.47
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther (2005) 2.47
KRAB-zinc finger proteins and KAP1 can mediate long-range transcriptional repression through heterochromatin spreading. PLoS Genet (2010) 2.44
Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol (2009) 2.36
Widespread expression of Huntington's disease gene (IT15) protein product. Neuron (1995) 2.29
Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol (2009) 2.19
Improved DNA binding specificity from polyzinc finger peptides by using strings of two-finger units. Proc Natl Acad Sci U S A (2001) 2.13
Recombinant AAV-mediated gene delivery to the central nervous system. J Gene Med (2004) 1.94
Factors influencing recombinant adeno-associated virus production. Hum Gene Ther (1998) 1.86
Transcriptional signatures in Huntington's disease. Prog Neurobiol (2007) 1.86
Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical disector methods. J Comp Neurol (1996) 1.80
Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther (2011) 1.72
Identification and allele-specific silencing of the mutant huntingtin allele in Huntington's disease patient-derived fibroblasts. Hum Gene Ther (2008) 1.71
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain (2012) 1.49
Huntington's Disease. Semin Neurol (2007) 1.43
Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein. Nat Biotechnol (2010) 1.38
Allele-specific silencing of mutant Huntington's disease gene. J Neurochem (2009) 1.35
Rational design of artificial zinc-finger proteins using a nondegenerate recognition code table. Biochemistry (2002) 1.26
Huntington's disease: pathogenesis to animal models. Pharmacol Rep (2010) 1.16
Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS One (2009) 1.15
Attraction to sexual pheromones and associated odorants in female mice involves activation of the reward system and basolateral amygdala. Eur J Neurosci (2005) 1.14
Zinc-finger directed double-strand breaks within CAG repeat tracts promote repeat instability in human cells. Proc Natl Acad Sci U S A (2009) 1.12
Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease. J Neurosci (2009) 1.11
Allele-selective inhibition of trinucleotide repeat genes. Drug Discov Today (2012) 1.08
The hybrid cytomegalovirus enhancer/chicken beta-actin promoter along with woodchuck hepatitis virus posttranscriptional regulatory element enhances the protective efficacy of DNA vaccines. J Immunol (2004) 1.06
Allele-selective inhibition of mutant huntingtin by peptide nucleic acid-peptide conjugates, locked nucleic acid, and small interfering RNA. Ann N Y Acad Sci (2009) 1.05
Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease. Philos Trans R Soc Lond B Biol Sci (1999) 1.03
The design of functional DNA-binding proteins based on zinc finger domains. Chem Rev (2004) 1.02
Stable and unstable transgene integration sites in the human genome: extinction of the Green Fluorescent Protein transgene in K562 cells. Gene (2000) 0.96
The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease. Brain Res Rev (2008) 0.96
Gene therapy for Huntington's disease. Neurobiol Dis (2011) 0.94
Dysregulation of dopamine receptor D2 as a sensitive measure for Huntington disease pathology in model mice. Proc Natl Acad Sci U S A (2012) 0.85
Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions. Methods Mol Biol (2010) 0.82
Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice. Mol Cell Biol (2002) 2.51
Diabetes risk gene and Wnt effector Tcf7l2/TCF4 controls hepatic response to perinatal and adult metabolic demand. Cell (2012) 2.45
Zinc-finger protein-targeted gene regulation: genomewide single-gene specificity. Proc Natl Acad Sci U S A (2003) 2.24
Computer design of obligate heterodimer meganucleases allows efficient cutting of custom DNA sequences. Nucleic Acids Res (2008) 1.74
Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev (2008) 1.73
Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol (2010) 1.61
Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol Cell Biol (2005) 1.52
X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options. Blood (2010) 1.51
Reproductive consequences of genome-wide paternal uniparental disomy mosaicism: description of two cases with different mechanisms of origin and pregnancy outcomes. Fertil Steril (2009) 1.49
Expression of epithelial cell adhesion molecule and pituitary tumor transforming gene in adamantinomatous craniopharyngioma and its correlation with recurrence of the tumor. Ann Diagn Pathol (2009) 1.45
DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. Am J Hum Genet (2008) 1.45
Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome. Exp Neurol (2012) 1.40
Erbb4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes. Neuron (2013) 1.34
Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc Natl Acad Sci U S A (2004) 1.31
Dyrk1A expression pattern supports specific roles of this kinase in the adult central nervous system. Brain Res (2003) 1.25
uPA deficiency exacerbates muscular dystrophy in MDX mice. J Cell Biol (2007) 1.22
Repression of the HIV-1 5' LTR promoter and inhibition of HIV-1 replication by using engineered zinc-finger transcription factors. Proc Natl Acad Sci U S A (2003) 1.21
A new mouse model for the trisomy of the Abcg1-U2af1 region reveals the complexity of the combinatorial genetic code of down syndrome. Hum Mol Genet (2009) 1.20
Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J Gen Virol (2006) 1.17
Differential effects of environmental enrichment on behavior and learning of male and female Ts65Dn mice, a model for Down syndrome. Behav Brain Res (2002) 1.17
Targeting the endocannabinoid system in the treatment of fragile X syndrome. Nat Med (2013) 1.16
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models. Neurobiol Dis (2005) 1.16
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans. Mol Nutr Food Res (2013) 1.15
Down syndrome: from understanding the neurobiology to therapy. J Neurosci (2010) 1.13
Impaired spatial learning strategies and novel object recognition in mice haploinsufficient for the dual specificity tyrosine-regulated kinase-1A (Dyrk1A). PLoS One (2008) 1.10
Inhibition of herpes simplex virus 1 gene expression by designer zinc-finger transcription factors. Proc Natl Acad Sci U S A (2003) 1.10
Overexpression of Reelin prevents the manifestation of behavioral phenotypes related to schizophrenia and bipolar disorder. Neuropsychopharmacology (2011) 1.08
Urokinase-type plasminogen activator receptor transcriptionally controlled adenoviruses eradicate pancreatic tumors and liver metastasis in mouse models. Neoplasia (2009) 1.06
Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Brain Res (2004) 1.06
Intraspecific communication through chemical signals in female mice: reinforcing properties of involatile male sexual pheromones. Chem Senses (2006) 1.06
CDKN1C (p57(Kip2)) analysis in Beckwith-Wiedemann syndrome (BWS) patients: Genotype-phenotype correlations, novel mutations, and polymorphisms. Am J Med Genet A (2010) 1.06
Cytogenetic study of spontaneous abortions using semi-direct analysis of chorionic villi samples detects the broadest spectrum of chromosome abnormalities. Am J Med Genet A (2008) 1.05
RhoE deficiency produces postnatal lethality, profound motor deficits and neurodevelopmental delay in mice. PLoS One (2011) 1.05
p53 Gene repair with zinc finger nucleases optimised by yeast 1-hybrid and validated by Solexa sequencing. PLoS One (2011) 1.04
Refining the dual olfactory hypothesis: pheromone reward and odour experience. Behav Brain Res (2008) 1.04
Proteomic analysis of the fetal brain. Proteomics (2002) 1.00
An animal model of compulsive food-taking behaviour. Addict Biol (2009) 0.99
Inhibition of human telomerase activity by an engineered zinc finger protein that binds G-quadruplexes. Biochemistry (2004) 0.98
Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling. Cell Stem Cell (2010) 0.97
Overexpression of the CHRNA5/A3/B4 genomic cluster in mice increases the sensitivity to nicotine and modifies its reinforcing effects. Amino Acids (2011) 0.96
Ceramide levels regulated by carnitine palmitoyltransferase 1C control dendritic spine maturation and cognition. J Biol Chem (2012) 0.96
Regression of advanced diabetic nephropathy by hepatocyte growth factor gene therapy in rats. Diabetes (2004) 0.94
MLPA as first screening method for the detection of microduplications and microdeletions in patients with X-linked mental retardation. Genet Med (2007) 0.92
Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. Neurobiol Dis (2013) 0.91
Screening for FXTAS in 95 Spanish patients negative for Huntington disease. Genet Test (2008) 0.91
Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Hum Mutat (2009) 0.91
DNA methylation map of mouse and human brain identifies target genes in Alzheimer's disease. Brain (2013) 0.91
Engineering prokaryotic gene circuits. FEMS Microbiol Rev (2008) 0.91
Building synthetic gene circuits from combinatorial libraries: screening and selection strategies. Mol Biosyst (2013) 0.91
Beta-amyloid controls altered Reelin expression and processing in Alzheimer's disease. Neurobiol Dis (2009) 0.90
Genetically encoded sender-receiver system in 3D mammalian cell culture. ACS Synth Biol (2013) 0.90
Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiol Dis (2006) 0.90
Non-invasive bioluminescence imaging for monitoring herpes simplex virus type 1 hematogenous infection. Microbes Infect (2006) 0.90
Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice. Neurobiol Dis (2009) 0.90
Behavioral characterization of a mouse model overexpressing DSCR1/ RCAN1. PLoS One (2011) 0.89
Prenatal cytogenetic diagnosis in Spain: analysis and evaluation of the results obtained from amniotic fluid samples during the last decade. Eur J Obstet Gynecol Reprod Biol (2011) 0.89
Intraductal delivery of adenoviruses targets pancreatic tumors in transgenic Ela-myc mice and orthotopic xenografts. Oncotarget (2013) 0.89
Fetal Down syndrome brains exhibit aberrant levels of neurotransmitters critical for normal brain development. Pediatrics (2007) 0.87
Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis (2012) 0.87
Irreversible electroporation shows efficacy against pancreatic carcinoma without systemic toxicity in mouse models. Cancer Lett (2011) 0.87
Dissociation between CA3-CA1 synaptic plasticity and associative learning in TgNTRK3 transgenic mice. J Neurosci (2007) 0.87
A biobrick library for cloning custom eukaryotic plasmids. PLoS One (2011) 0.86
Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing. PLoS One (2011) 0.86
Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors. Oncology (2005) 0.86
Targeting Dyrk1A with AAVshRNA attenuates motor alterations in TgDyrk1A, a mouse model of Down syndrome. Am J Hum Genet (2008) 0.86
Connexin-26 is a key factor mediating gemcitabine bystander effect. Mol Cancer Ther (2011) 0.85
Adenovirus-mediated retinoblastoma 94 gene transfer induces human pancreatic tumor regression in a mouse xenograft model. Clin Cancer Res (2004) 0.85
MLPA: a prenatal diagnostic tool for the study of congenital heart defects? Gene (2012) 0.85
Association of NTRK3 and its interaction with NGF suggest an altered cross-regulation of the neurotrophin signaling pathway in eating disorders. Hum Mol Genet (2008) 0.85
The gas-phase ozonolysis of beta-caryophyllene (C(15)H(24)). Part I: an experimental study. Phys Chem Chem Phys (2009) 0.85
Cell cycle control pathways act as conditioning factors for TK/GCV sensitivity in pancreatic cancer cells. Biochim Biophys Acta (2010) 0.84
Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations. Neurobiol Dis (2010) 0.84
Familial 4.8 MB deletion on 18q23 associated with growth hormone insufficiency and phenotypic variability. Am J Med Genet A (2012) 0.83
The PLOS ONE synthetic biology collection: six years and counting. PLoS One (2012) 0.83
NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect. PLoS One (2013) 0.83
Transgenic over expression of nicotinic receptor alpha 5, alpha 3, and beta 4 subunit genes reduces ethanol intake in mice. Alcohol (2012) 0.83
Cooperativity to increase Turing pattern space for synthetic biology. ACS Synth Biol (2014) 0.83
A gel-based proteomic method reveals several protein pathway abnormalities in fetal Down syndrome brain. J Proteomics (2011) 0.82
Description of the smallest critical region for Dandy-Walker malformation in chromosome 13 in a girl with a cryptic deletion related to t(6;13)(q23;q32). Am J Med Genet A (2010) 0.82
Fetoplacental discrepancy involving structural abnormalities of chromosome 8 detected by prenatal diagnosis. Prenat Diagn (2003) 0.82
Assessment of QF-PCR as the first approach in prenatal diagnosis. J Mol Diagn (2010) 0.82
Sexual pheromones and the evolution of the reward system of the brain: the chemosensory function of the amygdala. Brain Res Bull (2007) 0.82
Duplication/deletion mosaicism of the 7q(21.1 --> 31.3) region. Am J Med Genet A (2007) 0.82
Cas IIgly induces apoptosis in glioma C6 cells in vitro and in vivo through caspase-dependent and caspase-independent mechanisms. Neoplasia (2005) 0.82
Hippocampal hyperexcitability underlies enhanced fear memories in TgNTRK3, a panic disorder mouse model. J Neurosci (2013) 0.82
Positive selection of gene-modified cells increases the efficacy of pancreatic cancer suicide gene therapy. Mol Cancer Ther (2009) 0.81
Tat8-TK/GCV suicide gene therapy induces pancreatic tumor regression in vivo. Hum Gene Ther (2005) 0.81
Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future. Prog Brain Res (2012) 0.81
Targeting the CYP2B 1/cyclophosphamide suicide system to fibroblast growth factor receptors results in a potent antitumoral response in pancreatic cancer models. Hum Gene Ther (2006) 0.81
Autonomic, behavioral, and neural analyses of mild conditioned negative affect in marmosets. Behav Neurosci (2010) 0.80
In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model. Amino Acids (2010) 0.80
A novel Wiskott-Aldrich syndrome protein (WASP) complex mutation identified in a WAS patient results in an aberrant product at the C-terminus from two transcripts with unusual polyA signals. J Hum Genet (2005) 0.80
Wiskott-Aldrich syndrome in a female with skewed X-chromosome inactivation. Blood Cells Mol Dis (2003) 0.80
Keratin 7 promoter selectively targets transgene expression to normal and neoplastic pancreatic ductal cells in vitro and in vivo. FASEB J (2009) 0.79
AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway. J Neurochem (2013) 0.79
Carnitine palmitoyltransferase 1C deficiency causes motor impairment and hypoactivity. Behav Brain Res (2013) 0.79